Tags

Type your tag names separated by a space and hit enter

Evaluation of orally administered robenacoxib versus ketoprofen for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats.
Am J Vet Res 2010; 71(7):710-9AJ

Abstract

OBJECTIVE

To evaluate the efficacy and tolerability of oral administration of robenacoxib for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats.

ANIMALS

155 cats requiring relief of signs of pain and inflammation associated with acute musculoskeletal disorders.

PROCEDURES

The study was a multicenter, prospective, randomized, masked, noninferiority field trial. Cats were allocated randomly to 1 of 3 treatment groups: group 1 (1.0 to 2.4 mg of robenacoxib/kg, q 24 h), group 2 (1.0 to 2.4 mg of robenacoxib/kg, q 12 h [daily dosage, 2.0 to 4.8 mg/kg]), and group 3 (ketoprofen [mean dosage, 1 mg/kg, q 24 h]). All cats were administered tablets PO for 5 or 6 days. The primary efficacy endpoint was the investigator global assessment score, which was the sum of scores of signs of pain, inflammation, and mobility assessed in a masked manner by veterinary investigators at baseline, day 2, and day 4 or 5. Cat owners monitored in a nonmasked manner secondary responses by observation of cats' activity, behavior, appetite, and interactions. Safety was assessed by monitoring adverse events, clinical signs, and hematologic and plasma biochemical variables (before and after treatment).

RESULTS

No significant differences were detected among the 3 treatment groups for any primary or secondary efficacy endpoints or for tolerability variables. Robenacoxib tablets administered once daily were significantly more palatable than ketoprofen tablets.

CONCLUSIONS AND CLINICAL RELEVANCE

Robenacoxib tablets administered once daily had noninferior efficacy and tolerability, and superior palatability, compared with the active control drug, ketoprofen, for the treatment of signs of acute pain and inflammation associated with musculoskeletal disorders in cats.

Authors+Show Affiliations

Novartis Centre de Recherche Santé Animale SA, CH-1566 StAubin FR, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

20594071

Citation

Giraudel, Jerome M., et al. "Evaluation of Orally Administered Robenacoxib Versus Ketoprofen for Treatment of Acute Pain and Inflammation Associated With Musculoskeletal Disorders in Cats." American Journal of Veterinary Research, vol. 71, no. 7, 2010, pp. 710-9.
Giraudel JM, Gruet P, Alexander DG, et al. Evaluation of orally administered robenacoxib versus ketoprofen for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats. Am J Vet Res. 2010;71(7):710-9.
Giraudel, J. M., Gruet, P., Alexander, D. G., Seewald, W., & King, J. N. (2010). Evaluation of orally administered robenacoxib versus ketoprofen for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats. American Journal of Veterinary Research, 71(7), pp. 710-9. doi:10.2460/ajvr.71.7.710.
Giraudel JM, et al. Evaluation of Orally Administered Robenacoxib Versus Ketoprofen for Treatment of Acute Pain and Inflammation Associated With Musculoskeletal Disorders in Cats. Am J Vet Res. 2010;71(7):710-9. PubMed PMID: 20594071.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of orally administered robenacoxib versus ketoprofen for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats. AU - Giraudel,Jerome M, AU - Gruet,Philippe, AU - Alexander,Debbie G, AU - Seewald,Wolfgang, AU - King,Jonathan N, PY - 2010/7/3/entrez PY - 2010/7/3/pubmed PY - 2010/9/14/medline SP - 710 EP - 9 JF - American journal of veterinary research JO - Am. J. Vet. Res. VL - 71 IS - 7 N2 - OBJECTIVE: To evaluate the efficacy and tolerability of oral administration of robenacoxib for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats. ANIMALS: 155 cats requiring relief of signs of pain and inflammation associated with acute musculoskeletal disorders. PROCEDURES: The study was a multicenter, prospective, randomized, masked, noninferiority field trial. Cats were allocated randomly to 1 of 3 treatment groups: group 1 (1.0 to 2.4 mg of robenacoxib/kg, q 24 h), group 2 (1.0 to 2.4 mg of robenacoxib/kg, q 12 h [daily dosage, 2.0 to 4.8 mg/kg]), and group 3 (ketoprofen [mean dosage, 1 mg/kg, q 24 h]). All cats were administered tablets PO for 5 or 6 days. The primary efficacy endpoint was the investigator global assessment score, which was the sum of scores of signs of pain, inflammation, and mobility assessed in a masked manner by veterinary investigators at baseline, day 2, and day 4 or 5. Cat owners monitored in a nonmasked manner secondary responses by observation of cats' activity, behavior, appetite, and interactions. Safety was assessed by monitoring adverse events, clinical signs, and hematologic and plasma biochemical variables (before and after treatment). RESULTS: No significant differences were detected among the 3 treatment groups for any primary or secondary efficacy endpoints or for tolerability variables. Robenacoxib tablets administered once daily were significantly more palatable than ketoprofen tablets. CONCLUSIONS AND CLINICAL RELEVANCE: Robenacoxib tablets administered once daily had noninferior efficacy and tolerability, and superior palatability, compared with the active control drug, ketoprofen, for the treatment of signs of acute pain and inflammation associated with musculoskeletal disorders in cats. SN - 0002-9645 UR - https://www.unboundmedicine.com/medline/citation/20594071/Evaluation_of_orally_administered_robenacoxib_versus_ketoprofen_for_treatment_of_acute_pain_and_inflammation_associated_with_musculoskeletal_disorders_in_cats_ L2 - http://avmajournals.avma.org/doi/full/10.2460/ajvr.71.7.710?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -